CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding to tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, development of T-cell engagers has been limited due to challenges with efficacy and safety.
To address these challenges, we have developed a comprehensive T-cell engager platform to enable custom design and optimization of molecules based on a target product profile.
The poster below, which was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, demonstrates:
Strategies to address key challenges in TCE development:
- CD3-binding antibodies to widen the therapeutic window by generating TCEs with potent tumor cell-killing and optimal cytokine release
- Molecules to enhance efficacy for solid tumor indications by increasing T-cell activation and proliferation through costimulation of CD28 and 4-1BB
Application of the platform to two of AbCellera’s TCE programs:
Preclinical characterization of TCEs against solid tumor targets B7-H4 and PSMA show tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks.
